There is great news for parents suffering the harrowing ordeal of their child needing a bone marrow transplant. The announcement came from Osiris Therapeutics Inc. (NASDAQ: OSIR) on Friday that Health Canada has approved its groundbreaking stem cell therapy Prochymal® (remestemcel-L). The drug can be used to treat children with acute graft-vs-host disease. (GvHD).
The decision is a historic one, as it's both the first stem cell drug going into formal use, as well as the first treatment for GvHD. The disease is a devastating breakdown occurring after a bone marrow transplant and kills around 80% of children affected, often within a matter of weeks. . .View Full Article